Morphosys is developing the human CD38 antibody MOR202 that is being investigated as monotherapy and in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone in a phase I/II study in refractory or relapsed MM. Here, CD38 is linked to Miyoshi myopathy.